JP2014511682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511682A5 JP2014511682A5 JP2014501664A JP2014501664A JP2014511682A5 JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5 JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- molecule
- sequence
- dll4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 108700041286 delta Proteins 0.000 claims 3
- 101150109170 dll4 gene Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160920.2 | 2011-04-01 | ||
| EP11160920 | 2011-04-01 | ||
| PCT/EP2012/055897 WO2012131076A1 (en) | 2011-04-01 | 2012-03-30 | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511682A JP2014511682A (ja) | 2014-05-19 |
| JP2014511682A5 true JP2014511682A5 (enExample) | 2016-07-07 |
Family
ID=44314095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501664A Ceased JP2014511682A (ja) | 2011-04-01 | 2012-03-30 | Ｄｌｌ４及びＡｎｇ２と結合する二重特異性結合分子 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130078247A1 (enExample) |
| EP (1) | EP2694545B1 (enExample) |
| JP (1) | JP2014511682A (enExample) |
| KR (1) | KR20140016345A (enExample) |
| CN (2) | CN103596977B (enExample) |
| AP (1) | AP2013007086A0 (enExample) |
| AR (1) | AR085919A1 (enExample) |
| AU (1) | AU2012234218A1 (enExample) |
| BR (1) | BR112013025294A2 (enExample) |
| CA (1) | CA2827809A1 (enExample) |
| CL (1) | CL2013002622A1 (enExample) |
| CO (1) | CO6801638A2 (enExample) |
| EA (1) | EA201301109A1 (enExample) |
| EC (1) | ECSP13012996A (enExample) |
| MA (1) | MA35233B1 (enExample) |
| MX (1) | MX337115B (enExample) |
| PE (1) | PE20141157A1 (enExample) |
| PH (1) | PH12013502031A1 (enExample) |
| SG (1) | SG193557A1 (enExample) |
| TN (1) | TN2013000389A1 (enExample) |
| TW (2) | TWI551612B (enExample) |
| UY (1) | UY33997A (enExample) |
| WO (1) | WO2012131076A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PL2831111T3 (pl) * | 2012-03-30 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Cząsteczki wiążące Ang2 |
| US20140093498A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| WO2014049100A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| CN107540747B (zh) * | 2017-08-09 | 2020-01-24 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体6f12 |
| CN110950967B (zh) * | 2019-12-13 | 2022-05-13 | 山东民康生物科技有限公司 | 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法 |
| EP4400512A4 (en) * | 2021-09-10 | 2025-07-23 | Soter Biopharma Pte Ltd | ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE |
| JP2025533028A (ja) * | 2022-09-28 | 2025-10-03 | 科▲興▼生物制▲薬▼股▲ふん▼有限公司 | Ａｎｇ－２を認識できる抗体または抗原結合断片及びｖｅｇｆとａｎｇ－２を同時に認識できる二重抗体 |
| CN116444675B (zh) * | 2023-05-11 | 2023-12-22 | 亲和(武汉)生命科技有限责任公司 | 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用 |
| KR20260117748A (ko) * | 2023-11-28 | 2026-07-29 | 에프. 호프만-라 로슈 아게 | 혈관형성, 염증 및/또는 섬유화 인자를 표적으로 하는 다중특이적 융합 단백질 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| PL1962895T3 (pl) * | 2005-12-16 | 2013-06-28 | Regeneron Pharma | Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów |
| CN101489576A (zh) * | 2006-06-06 | 2009-07-22 | 健泰科生物技术公司 | 用于调节血管发育的组合物和方法 |
| JP2009539870A (ja) | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
| AU2007319672B2 (en) * | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2626372B1 (en) * | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102264763B (zh) * | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| UY32917A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
-
2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/en not_active Ceased
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh not_active IP Right Cessation
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/en not_active Not-in-force
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 CA CA2827809A patent/CA2827809A1/en not_active Abandoned
-
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515602A5 (enExample) | ||
| HRP20190817T1 (hr) | Ang2-vezujuće molekule | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2013502204A5 (enExample) | ||
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| JP2010502207A5 (enExample) | ||
| JP2017524339A5 (enExample) | ||
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2015532292A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| WO2011039368A3 (en) | Dll4-binding molecules | |
| WO2017009308A3 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| JP2016502515A5 (enExample) | ||
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| MY171007A (en) | Bispecific binding molecules binding to vegf and ang2 | |
| BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| JP2016524463A5 (enExample) | ||
| IL187321A (en) | Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments |